CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Darolutamide (Nubeqa) for Non-Metastatic Castration Resistant Prostate Cancer – Details

Project Number PC0196-000
Brand Name Nubeqa
Generic Name Darolutamide
Strength 300 mg
Tumour Type Genitourinary
Indication Non-Metastatic Castration Resistant Prostate Cancer
Funding Request In combination with androgen depravation therapy (ADT), for the treatment of patients with non-metastatic castration resistant prostate cancer who are at high risk of developing metastases (high risk defined as prostate-specific antigen doubling time ≤ 10 months) during continuous ADT, and have a good Eastern Cooperative Oncology Group (ECOG) performance status
Review Status Complete
Pre Noc Submission Yes
NOC Date February 20, 2020
Manufacturer Bayer Inc.
Sponsor Bayer Inc.
Submission Date August 27, 2019
Submission Deemed Complete September 11, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ September 11, 2019
Check-point meeting November 12, 2019
pERC Meeting March 19, 2020
Initial Recommendation Issued April 2, 2020
Feedback Deadline ‡ April 17, 2020
Final Recommendation Issued April 22, 2020
Notification to Implement Issued May 7, 2020
Therapeutic Area non-metastatic castration resistant prostate cancer (nmCRPC)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.